May 09, 2018
Harish Manwani Joins Gilead Sciences’ Board of Directors
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 9, 2018--
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Harish M.
Manwani has been appointed to the company’s Board of Directors.
Mr. Manwani is a Global Executive Advisor to the private equity business
of Blackstone, a leading asset management company. He was previously
Chief Operating Officer of the global consumer products company Unilever
PLC. He began his career at Unilever in 1976 and held senior management
positions in Unilever businesses around the world for nearly 40 years.
He brings broad international operational expertise, having worked
extensively in Asia, Africa, Europe and the Americas. Mr. Manwani is
currently the Chairman of Hindustan Unilever Ltd., and serves on the
Boards of Nielsen Holdings PLC, Qualcomm Inc. and Whirlpool Corp. He is
also on the Board of Economic Development Board of Singapore and is the
Chairman of the Board of Indian School of Business.
“We are very pleased to welcome Harish Manwani to our Board of
Directors,” said John Milligan, Ph.D., President and Chief Executive
Officer, Gilead Sciences. “Harish brings extensive experience in driving
growth across complex organizations on a global scale. His expertise
will help guide our strategy as Gilead continues to grow in new
geographies and address unmet medical needs for people around the world.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Gilead has operations in more
than 35 countries worldwide, with headquarters in Foster City,
California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180509006474/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Mark
Snyder, 650-522-6167
